Yasuaki Takeji

Yasuaki Takeji

Auto-generated profile, based on publicly available information

Yasuaki Takeji

Kanazawa University Graduate School of Medical Sciences

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
KYKo Yamamoto
Ko Yamamoto
MNMasahiro Natsuaki
Masahiro Natsuaki
TMTakeshi Morimoto
Takeshi Morimoto
HSHiroki Shiomi
Hiroki Shiomi
YMYukiko Matsumura-Nakano
Yukiko Matsumura-Nakano
TKTakeshi Kimura
Takeshi Kimura

24 April 2020 in Circulation Journal
Verified
Journal Article
Open access
PDF file
YTYasuaki Takeji
Yasuaki Takeji
TTTomohiko Taniguchi
Tomohiko Taniguchi
TMTakeshi Morimoto
Takeshi Morimoto
NSNaritatsu Saito
Naritatsu Saito
KAKenji Ando
Kenji Ando
OIon behalf of the CURRENT AS Registry Investigators and K-TAVI Registry Investigators
on behalf of the CURRENT AS Registry Investigators and K-TAVI Registry Investigators
Background:There are no data comparing transcatheter aortic valve implantation (TAVI) with surgical aortic valve replacement (SAVR) outcomes in real clinical practice in Japan. Methods and Results:We combined 2 independent registries, the K-TAVI Registry (a 6-center prospective registry of consecutive patients who underwent TAVI) and the CURRENT AS Registry (a large, 27-center registry of 3,815 consecutive patients with severe aortic stenosis [AS]). In the K-TAVI Registry, 338 patients underwent TAVI with SAPIEN XT balloon-expandable valves from October 2013 to January 2016, whereas in the CURRENT AS Registry 237 patients with severe AS underwent SAVR from January 2003 to December 2011. Propensity score matching was conducted, with final cohort comprising 306 patients. The cumulative 2-year incidence of all-cause death and heart failure (HF) hospitalization did not differ significantly between the TAVI and SAVR groups (13.7% vs. 12.4% [P=0.81] and 7.9% vs 3.9% [P=0.13], respectively). After adjusting for residual confounders, there were no significant differences between the TAVI and SAVR groups in the risk for all-cause death (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.35–1.58; P=0.43) or HF hospitalization (HR 1.27; 95% CI 0.40–4.59; P=0.69). Conclusions:These findings from 2 independent Japanese registries suggest that the 2-year risk of all-cause mortality and HF does not differ significantly between TAVI and SAVR groups in real-world practice in Japan.

16 July 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
KYKo Yamamoto
Ko Yamamoto
HUHiroyuki Ueda
Hiroyuki Ueda
DUDaiji Uchiyama
Daiji Uchiyama
YTYasuaki Takeji
Yasuaki Takeji
TTTomohiko Taniguchi
Tomohiko Taniguchi
TKTakeshi Kimura
Takeshi Kimura
Background: There is a scarcity of data on the prevalence and clinical impact of cerebrovascular disease detected on preprocedural computed tomography (CT) before aortic valve replacement (AVR) in patients with severe aortic stenosis. Methods and Results: Among patients with severe aortic stenosis undergoing AVR, the authors compared clinical outcomes between patients with and without cerebrovascular disease detected on preprocedural CT, which was defined as chronic brain infarction or hemorrhage. The primary outcome measure in this study was a composite of all‐cause death or stroke. Among 567 study patients, 200 patients (35.3%) had cerebrovascular disease on preprocedural CT. Among 200 patients with cerebrovascular disease on preprocedural CT, only 28.5% of patients had a clinical history of symptomatic stroke. The cumulative 3‐year incidence of death or stroke was higher in patients with cerebrovascular disease on preprocedural CT than in those without cerebrovascular disease on preprocedural CT (40.7% versus 24.1%, log‐rank P <0.001). After adjusting for confounders, the higher risk of patients with cerebrovascular disease on preprocedural CT relative to those without remained significant for death or stroke (hazard ratio [HR], 1.42 [95% CI, 1.02–1.98]; P =0.04). Among 200 patients with cerebrovascular disease on preprocedural CT, patients with prior symptomatic stroke compared with those without were not associated with higher adjusted risk for death or stroke (HR, 1.18 [95% CI, 0.72–1.94]; P =0.52). Conclusions: Among patients with severe aortic stenosis undergoing AVR, a substantial proportion had cerebrovascular disease on preprocedural CT, with a clinical history of symptomatic stroke in one‐fourth of patients. Regardless of history of symptomatic stroke, patients with cerebrovascular disease on preprocedural CT had worse clinical outcomes compared with those without cerebrovascular disease on preprocedural CT.

23 November 2021 in JACC: Asia
Verified
Journal Article
Open access
YYYusuke Yoshikawa
Yusuke Yoshikawa
HSHiroki Shiomi
Hiroki Shiomi
TMTakeshi Morimoto
Takeshi Morimoto
YTYasuaki Takeji
Yasuaki Takeji
YMYukiko Matsumura-Nakano
Yukiko Matsumura-Nakano
TKTakeshi Kimura
Takeshi Kimura
There are limited data on the long-term stent-related adverse events as related to the duration of dual antiplatelet therapy (DAPT) in second-generation (G2) drug-eluting stents (DES) compared with first-generation (G1) DES. This study sought to compare the long-term stent-related outcomes of G2-DES with those of G1-DES. The study group consisted of 15,009 patients who underwent their first coronary revascularization with DES from the CREDO-Kyoto PCI/CABG (Coronary Revascularization Demonstrating Outcome Study in Kyoto Percutaneous Coronary Intervention/Coronary Artery Bypass Grafting) Registry Cohort-2 (first-generation drug-eluting stent [G1-DES] period; n = 5,382) and Cohort-3 (second-generation drug eluting stent [G2-DES] period; n = 9,627). The primary outcome measures were definite stent thrombosis (ST) and target vessel revascularization (TVR). The cumulative 5-year incidences of definite ST and TVR were significantly lower in the G2-DES group than in the G1-DES group (0.7% vs 1.4%; P < 0.001; and 16.2% vs 22.1%; P < 0.001, respectively). The lower adjusted risk of G2-DES relative to G1-DES for definite ST and TVR remained significant (HR: 0.53; 95% CI: 0.37-0.76; P < 0.001; and HR: 0.74; 95% CI: 0.68-0.81; P < 0.001, respectively). In the landmark analysis that was based on the DAPT status at 1 year, the lower adjusted risk of on-DAPT status relative to off-DAPT was significant for definite ST beyond 1 year in the G1-DES stratum (HR: 0.42; 95% CI: 0.24-0.76; P = 0.004) but not in the G2-DES stratum (HR: 0.66; 95% CI: 0.26-1.68; P = 0.38) (Pinteraction = 0.14). G2-DES compared with G1-DES were associated with a significantly lower risk for stent-related adverse events, including definite ST and TVR. DAPT beyond 1 year was associated with a significantly lower risk for very late ST of G1-DES but not for that of G2-DES.

27 August 2025 in JACC: Advances
Verified
Journal Article
Open access
YTYasuaki Takeji
Yasuaki Takeji
TTTomohiko Taniguchi
Tomohiko Taniguchi
TMTakeshi Morimoto
Takeshi Morimoto
SSShinichi Shirai
Shinichi Shirai
TKTakeshi Kitai
Takeshi Kitai
CICURRENT AS registry-2 Investigators
CURRENT AS registry-2 Investigators
The prognostic impact of cardiac damage staging in severe aortic stenosis (AS) based on gradient patterns, symptoms, and initial treatment strategies is not well understood. This study aimed to assess the differences in characteristics and clinical outcomes of AS patients according to cardiac damage stage, stratified by gradient patterns, symptoms, and treatment strategies. A total of 3,369 consecutive patients with severe AS (high-gradient [HG] AS, n = 1986; low-gradient [LG] AS, n = 1,383) from the CURRENT AS registry-2 were included. Cardiac damage was categorized into 4 groups (stage 0, stage 1, stage 2, and stage 3/4). The cumulative incidence of the primary outcome (all-cause death or heart failure hospitalization) increased with advancing cardiac damage stages in both HG and LG AS. Adjusted HRs for stages 1, 2, and 3/4 vs stage 0 were significantly higher in both HG and LG cohorts (HG AS: HR: 2.47; 95% CI: 1.23-4.96 [stage 1]; HR: 3.39; 95% CI: 1.72-6.67 [stage 2]; HR: 4.01; 95% CI: 1.95-8.25 [stage 3/4]; LG AS: HR: 1.72; 95% CI: 1.04-2.84 [stage 1]; HR: 2.28; 95% CI: 1.44-3.61 [stage 2]; HR: 2.95; 95% CI: 1.79-4.88 [stage 3/4]). The higher risk of the primary outcome with more advanced cardiac damage was consistent regardless of the presence of symptoms and the initial treatment strategies in both HG and LG AS. Cardiac damage staging is a useful tool for prognostic stratification in patients with severe AS, independent of gradient patterns, symptoms, and initial treatment strategies.

7 June 2025 in The American Journal of Cardiology
Verified
Journal Article
Closed access
YTYasuaki Takeji
Yasuaki Takeji
TTTomohiko Taniguchi
Tomohiko Taniguchi
TMTakeshi Morimoto
Takeshi Morimoto
SSShinichi Shirai
Shinichi Shirai
TKTakeshi Kitai
Takeshi Kitai
CICURRENT AS Registry-2 Investigators
CURRENT AS Registry-2 Investigators